It affects 4 in 10 adults. Left unaddressed, it strains your heart and liver. So why do doctors still treat it as a cosmetic issue?

Access to obesity medicine specialists remains limited under many insurance plans, leaving millions of patients without a clear path to treatment.

It's one of the most common complaints in American medicine, but one of the least likely to be addressed at its root. Dr. Marissa Blane has spent over a decade studying metabolic hormone signaling and appetite regulation. Her clinical work has focused on why so many patients who “eat right and still can't lose weight” are being told it's a willpower problem, when the underlying biology tells a different story. In an interview with our health desk, she explains why the standard approach to weight management is failing millions of Americans, and what patients need to know.

The numbers are hard to ignore. More than 4 in 10 U.S. adults are now living with obesity, according to CDC data, and stubborn midsection fat is one of the most frequently reported concerns in primary care visits. Modern lifestyles — processed food, chronic stress, disrupted sleep, and long sedentary hours — all suppress the body's natural GLP-1 signaling, the hormone responsible for telling your brain “you've had enough.” When that signal is weak, portion control stops being a matter of discipline and becomes a losing battle against constant “food noise.” Left unaddressed, excess visceral fat is associated with insulin resistance, elevated blood pressure, and long-term strain on the heart and liver.

That is why I consider chronically low GLP-1 activity a genuine driver of the obesity epidemic — one that deserves far more attention in a standard ten-minute appointment than it currently gets.

Partly because patients are told it's a lifestyle issue long before anyone looks at the hormonal picture. By the time someone raises the topic with their family doctor — already a challenge given how booked most practices are — they've often tried and failed at several diets already. The doctor has about ten minutes to review a full list of concerns, and appetite regulation rarely makes it to the top. If a GLP-1 medication is discussed at all, patients quickly run into the real barriers: insurance plans that only approve coverage for patients who meet a strict diabetes or BMI threshold, months-long waits to see an endocrinologist, and list prices for injectable GLP-1 drugs that can run several hundred dollars a month out of pocket.

Coverage for GLP-1 medications varies drastically by plan and state, leaving many patients to pay out of pocket or go without treatment.

Even patients who do get approved often discover the coverage is temporary, or that their co-pay jumps the moment a manufacturer's savings card expires. It depends entirely on your plan and your state: someone with employer coverage in one state might pay $25 a month, while someone one state over is quoted the full retail price. General practitioners are stretched thin, managing a growing list of chronic conditions in short visits, and appetite regulation — perceived as a “lifestyle issue” — is too easily pushed to the bottom of the list.

It's not a lack of experience, it's a combination of time pressure, cost, and access. Your doctor may suggest a calorie-tracking app or a referral to a dietitian with a three-month waitlist. These can help with awareness, but they don't change the underlying hormonal signal driving the cravings. Injectable GLP-1 medications are the most effective pharmaceutical option available, but they require a prescription, ongoing doctor visits, refrigerated storage, and carry a well-documented list of side effects — nausea, vomiting, and in some cases loss of lean muscle mass. The result is a treatment landscape where the most effective option is often the least accessible one.

Most physicians agree that diet advice alone rarely works for patients with genuinely low GLP-1 activity. Yet that's exactly what most patients are sent home with. What's needed is a practical, accessible way to support the body's own GLP-1 production — something patients can use daily without needles, refrigeration, or a several-hundred-dollar monthly bill. Training more obesity-medicine specialists would help, but that's a years-long project. In the meantime, there's encouraging progress on the transdermal side of the category: nutrient-based patches designed to support — not replace — the body's natural GLP-1 pathway.

For patients who can't tolerate injections, can't get approved by their insurance, or simply want a non-invasive daily option, Ledisa offers a practical alternative. It's a once-daily transdermal patch built around ingredients studied for their role in supporting the body's own GLP-1 signaling and gut-brain satiety pathway — without needles, prescriptions, or the side-effect profile associated with injectable medications.

Ledisa is designed to fit into a normal daily routine — no fridge, no needles, no clinic visits.

Ledisa was developed specifically around the two ingredients most consistently studied for GLP-1 support: Berberine and low-molecular-weight Prebiotics. Many competing “GLP-1 patches” list Berberine on the label but skip Prebiotics entirely, or use a standard prebiotic form that's too large a molecule to pass through the skin. To actually absorb transdermally, Prebiotics need to be refined below roughly 1,000 Daltons — a level of processing only a handful of suppliers worldwide can produce, which is why so many competing patches quietly leave it out.

Berberine on its own acts as a spark, prompting the gut's L-cells to release more GLP-1. But without Prebiotics to feed the beneficial bacteria that keep those cells active, the effect can fade quickly — what researchers sometimes describe as a hunger “spike and crash.” Ledisa was built to pair the two together in a single daily patch, worn discreetly on the stomach or arm for eight hours, so the body gets a steady, cumulative signal rather than a one-time nudge.

INJECTABLE GLP-1 MEDICATIONS (Ozempic, Wegovy, etc.)

Highly effective for many patients, but require a prescription, ongoing doctor visits, refrigerated storage, needles, and can cost several hundred dollars a month without insurance approval. Common side effects include nausea, vomiting, and lean muscle loss.

Many competing patches list Berberine on the label but leave out Prebiotics entirely, or don't disclose whether the Prebiotics used are in the low-molecular-weight form required to actually absorb through the skin.

Foundational and important — but for patients with genuinely low GLP-1 signaling, willpower alone is fighting against biology, which is why so many people plateau despite real effort.

LEDISA

Consistent daily use is the biggest factor in the results patients report.

Most customers are advised to commit to at least 4–8 weeks of consistent daily use before evaluating results, since the gut-brain signaling pathway responds gradually rather than overnight.

Ledisa is a topical patch intended for adults and applied to clean, intact skin on the stomach or arm. As with any topical product, discontinue use if irritation occurs, and avoid applying to broken or irritated skin.

Ledisa ships directly within the U.S., typically within 2–4 business days. Ordering takes a few minutes on the official site — no prescription required.

Topics: HEALTH & METABOLISM, Ledisa, Health

Every order comes with a 90-day, no-questions-asked satisfaction guarantee — if you don't feel a difference, let the team know within 90 days for a resolution. Because access to effective, affordable metabolic support varies so widely depending on insurance and location, Ledisa is currently offering a limited-time discount on full courses so cost isn't the barrier standing between patients and consistent daily use.